UniQure gene therapy shows promising result in mid-stage trial [Reuters (UK)]
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: Reuters
UniQure gene therapy shows promising result in mid-stage trial | Reuters 3 Min Read (Reuters) - Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study. Common treatments for hemophilia B, in which a lack of the protein factor IX (FIX) prevents clotting that could lead to severe bleeding, include factor replacement therapy where the patient gets an injection of clotting protein. Spark Therapeutics and Pfizer Inc are also developing a gene therapy for treating hemophilia B. UniQure’s treatment aims to reduce bleeding by raising the FIX levels, and no patient suffered bleeding or needed replacement therapy during the trial period. “With the FIX activity observed to date, we believe these patients could feel better without seeing signs of disease,” Cantor Fitzgerald analyst Elemer Piros said. The updated data from a mid-stage study showed that all three patients
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- uniQure (NASDAQ: QURE) had its price target lowered by analysts at Mizuho from $10.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
- uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- uniQure (NASDAQ: QURE) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- uniQure (NASDAQ: QURE) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $8.00 price target on the stock.MarketBeat
- uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswire
QURE
Earnings
- 11/7/23 - Miss
QURE
Sec Filings
- 4/12/24 - Form PRE
- 4/12/24 - Form 8-K
- 3/5/24 - Form 4
- QURE's page on the SEC website